BioMarin Q3 Loss Narrower Than Expected, View Raised By: TalkMarkets October 24, 2014 at 15:58 PM EDT The raised outlook reflects the continued strong performance of Vimizim and updated expectations. The market responded positively today. Read More >> Related Stocks: Biomarin Pharmaceuticals Illumina Inc Sanofi-Aventis S.A. ADR